CASP3 and neoplasm: At an early time point (5 days of treatment), before any significant changes in tumor volumes, we observed a decrease in proliferation marker Ki67 staining in all drug treatment groups (Fig 2C), while there was no induction of apoptosis marker cleaved caspase 3 at this timepoint (Fig 2D).